Research Progress and Clinical Translation Challenges of Small‐Molecule Inhibitors Targeting PD‐L1
ChemMedChem · 2026
DOI: 10.1002/cmdc.202500972 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift ChemMedChem, 2026. Verfasst von Liang Qian und 6 weiteren Autor:innen. Beteiligte Einrichtung: Lab of Chemical Biology and Molecular Drug Design, College of Pharmaceutical Science, Zhejiang University of Technology, Deqing, China. Hauptthemen laut MEDLINE: Small Molecule Libraries, B7-H1 Antigen, Antineoplastic Agents. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 119 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Zhejiang Leading Innovation and Entrepreneurship Team.
Abstract (Originalsprache)
Antibody‐based drugs targeting the PD‐1/PD‐L1 axis have become widely used in clinical treatments. However, challenges such as high costs and suboptimal clinical response rates have fueled growing interest in developing small‐molecule inhibitors. Recent clinical trials, both domestically and internationally, have evaluated several small‐molecule inhibitors. Notable compounds like CA‐170 and INCB086550 have shown promising properties and potential in these studies. Although no small‐molecule inhibitors targeting PD‐L1 have yet been approved for clinical use, the path to their development and clinical translation is fraught with challenges. Researchers are actively exploring innovative strategies for drug design and synthesis, while carefully assessing critical factors such as safety and efficacy. Given the essential role of the PD‐1/PD‐L1 pathway in immune evasion by tumors, this review provides a concise overview of the signaling and structure of PD‐1/PD‐L1, summarizes current progress on clinical candidate drugs targeting this pathway, discusses the challenges in translating small‐molecule inhibitors to clinical practice, and outlines future directions in drug development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Lab of Chemical Biology and Molecular Drug Design, College of Pharmaceutical Science, Zhejiang University of Technology, Deqing, China.
- Institute of Drug Development & Chemical Biology, Zhejiang University of Technology, Deqing, China.
- Kecheng Industrial Development Institute, Zhejiang University of Technology, Quzhou, China.
- Zhejiang Jieyuan Med-Tech Co., Ltd., Hangzhou, China.
ORCID-Profile: Annoor Awadasseid, Wen Zhang
Förderung
- National Natural Science Foundation of China
- Zhejiang Leading Innovation and Entrepreneurship Team
Zitieren
APA
Qian, L., Ni, R., Lv, P., Chai, Y., Awadasseid, A., Xiong, X., & Zhang, W. (2026). Research Progress and Clinical Translation Challenges of Small‐Molecule Inhibitors Targeting PD‐L1. ChemMedChem. https://doi.org/10.1002/cmdc.202500972
Vancouver
Qian L, Ni R, Lv P, Chai Y, Awadasseid A, Xiong X, et al. Research Progress and Clinical Translation Challenges of Small‐Molecule Inhibitors Targeting PD‐L1. ChemMedChem. 2026. doi:10.1002/cmdc.202500972
BibTeX
@article{Qian2026,
author = {Qian, Liang and Ni, Ruyue and Lv, Ping and Chai, Yuxing and Awadasseid, Annoor and Xiong, Xuqiong and Zhang, Wen},
title = {Research Progress and Clinical Translation Challenges of Small‐Molecule Inhibitors Targeting PD‐L1},
journal = {ChemMedChem},
year = {2026},
doi = {10.1002/cmdc.202500972}
}
EUVIMED